Mark R. Middleton
Impact in
- Oncology top 0.1%
- Cutaneous Melanoma Detection and Management
- CAR-T cell therapy research
- Cancer Immunotherapy and Biomarkers
- PARP inhibition in cancer therapy
- Immunology top 1%
- Immunotherapy and Immune Responses
Papers in
- Oncology 169
- CAR-T cell therapy research 57
- Cancer Immunotherapy and Biomarkers 53
- Cutaneous Melanoma Detection and Management 31
- PARP inhibition in cancer therapy 22
-
- Melanoma and MAPK Pathways 54
- Co-authors
- Jean‐Jacques Grob (12 shared papers)Fergus Gleeson (16 shared papers)Feng Wu (10 shared papers)David Cranston (6 shared papers)Gail ter Haar (6 shared papers)Geoffrey P. Margison (18 shared papers)Philippe Saïag (5 shared papers)Hubert Pehamberger (5 shared papers)
- Journals
- Journal of Clinical Oncology (78 papers)Annals of Oncology (33 papers)British Journal of Cancer (25 papers)Clinical Cancer Research (17 papers)European Journal of Cancer (16 papers)
- Partner nations
- United KingdomUnited StatesAustralia
In The Last Decade
Mark R. Middleton
363 papers receiving 14.0k citations
Mark R. Middleton's Hit Papers
Peers
Comparison fields: 5 of 163
- Oncology 6.5k
- Immunology 2.0k
- Molecular Biology 5.7k
- Cancer Research 1.1k
- Genetics 741
Countries citing papers authored by Mark R. Middleton
This map shows the geographic impact of Mark R. Middleton's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark R. Middleton with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark R. Middleton more than expected).
Fields of papers citing papers by Mark R. Middleton
This network shows the impact of papers produced by Mark R. Middleton. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark R. Middleton. The network helps show where Mark R. Middleton may publish in the future.
Co-authors
The 25 scholars most cited alongside Mark R. Middleton, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 375 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Randomized Phase III Study of Temozolomide Versus Dacarbazine in the Treatment of Patients With Advanced Metastatic Malignant Melanoma Hit paper breakdown → | 2000 | 986 |
| 2 | 2005 | 497 | |
| 3 | Diagnosis and treatment of Merkel Cell Carcinoma. European consensus-based interdisciplinary guideline Hit paper breakdown → | 2015 | 381 |
| 4 | 2004 | 376 | |
| 5 | 2016 | 366 | |
| 6 | Diagnosis and treatment of invasive squamous cell carcinoma of the skin: European consensus-based interdisciplinary guideline Hit paper breakdown → | 2015 | 354 |
| 7 | Final analyses of OPTiM: a randomized phase III trial of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor in unresectable stage III–IV melanoma Hit paper breakdown → | 2019 | 326 |
| 8 | 2008 | 324 | |
| 9 | Phosphatidylinositol 3-Kinase α–Selective Inhibition With Alpelisib (BYL719) in PIK3CA-Altered Solid Tumors: Results From the First-in-Human Study Hit paper breakdown → | 2018 | 310 |
| 10 | 2010 | 250 | |
| 11 | 2009 | 232 | |
| 12 | 2011 | 228 | |
| 13 | 2020 | 206 | |
| 14 | 2018 | 192 | |
| 15 | 2005 | 190 | |
| 16 | 2020 | 182 | |
| 17 | 2018 | 182 | |
| 18 | 2012 | 169 | |
| 19 | 2017 | 161 | |
| 20 | 2013 | 157 |
About Mark R. Middleton
Mark R. Middleton is a scholar working on Oncology, Molecular Biology, Immunology, Pulmonary and Respiratory Medicine and Surgery, having authored 375 papers that have together received 14.3k indexed citations. Recurring topics across this work include CAR-T cell therapy research (57 papers), Melanoma and MAPK Pathways (54 papers), Cancer Immunotherapy and Biomarkers (53 papers), Immunotherapy and Immune Responses (39 papers), Cutaneous Melanoma Detection and Management (31 papers), Esophageal Cancer Research and Treatment (23 papers), PARP inhibition in cancer therapy (22 papers) and Cancer Genomics and Diagnostics (18 papers). The work is most often cited by research in Oncology (6.5k citations), Immunology (2.0k citations), Molecular Biology (5.7k citations), Cancer Research (1.1k citations) and Genetics (741 citations). Mark R. Middleton has collaborated with scholars based in United Kingdom, United States and Australia. Frequent co-authors include Jean‐Jacques Grob, Fergus Gleeson, Feng Wu, David Cranston, Gail ter Haar, Geoffrey P. Margison, Philippe Saïag, Hubert Pehamberger, Claus Garbe and Josep Malvehy. Their work appears in journals such as Journal of Clinical Oncology, Annals of Oncology, British Journal of Cancer, Clinical Cancer Research and European Journal of Cancer.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.